Progestosterone induces cell apoptosis via the CACNA2D3/Ca\(^{2+}\)/p38 MAPK pathway in endometrial cancer

XIANGNAN KONG\(^1\)*, MIN LI\(^2\)*, KAI SHAO\(^1,3\), YINRONG YANG\(^1\), QIAN WANG\(^1\) and MEIJUAN CAI\(^1\)

\(^1\)Department of Clinical Laboratory, \(^2\)Department of Gynecology, Qilu Hospital of Shandong University, Jinan, Shandong 250012; \(^3\)Qingdao Key Lab of Mitochondrial Medicine, Qilu Hospital of Shandong University (Qingdao), Qingdao, Shandong 266035, P.R. China

Received July 9, 2019; Accepted October 15, 2019

DOI: 10.3892/or.2019.7396

Abstract. Endometrial cancer (EC) is one of the most common malignant gynecological tumors in women. The main treatments for EC (surgery, chemotherapy and radiation therapy) produce significant side effects. Thus, it is urgent to identify promising therapeutic targets and prognostic markers. CACNA2D3, as a member of the calcium channel regulatory α2δ subunit family, is reported to exert a tumor suppressive effect in numerous cancers. However, the function of CACNA2D3 in EC is not well known. In the present study, CACNA2D3 was weakly expressed in EC tissues and cells. The overexpression of CACNA2D3 via lentiviral particle injection significantly blocked the tumor growth in an in vivo xenograft model. In vitro, the overexpression of CACNA2D3 markedly inhibited cell proliferation and migration, and promoted cell apoptosis and calcium influx. These data revealed that CACNA2D3 functions as a tumor suppressor in EC. It was also revealed that the addition of progesterone (P4) blocked tumor growth in Ishikawa-injected nude mice. P4 induced the expression of CACNA2D3 in vivo and in vitro, and the silencing of CACNA2D3 affected P4-inhibited cell proliferation and P4-induced cell apoptosis and calcium influx. In Ishikawa cells, P4 enhanced the expression of phosphorylated (p)-p38 MAPK and PTEN, but blocked the levels of p-PI3K and p-AKT. The knockdown of CACNA2D3 blocked the function of P4. These data revealed that P4 promoted cell apoptosis via the activation of the CACNA2D3/Ca\(^{2+}\)/p38 MAPK pathway, and blocked cell proliferation via suppression of the PI3K/AKT pathway. Collectively, these findings indicated the antitumor role of CACNA2D3 in EC, and revealed the mechanism of P4 inhibition of EC progression, which provided a new target for EC therapy and new evidence for P4 in EC therapy.

Introduction

Endometrial cancer (EC) is one of the most common malignant gynecological tumors (1) and remains a major cause of cancer-associated morbidity and mortality among women (2). With changes in western lifestyles and the rising prevalence of obesity in developing counties, the incidence of EC has increased, and is becoming increasingly more common in younger individuals in China (3). Current treatments for EC primarily include surgery, chemotherapy and radiation therapy, which are associated with notable side effects (4). In addition, in some young early-stage patients with EC, preserving their fertility is required. Therefore, elucidation of the molecular mechanisms underlying EC may assist in identifying and developing promising therapeutic targets and prognostic markers. The ovarian steroid hormones, estrogen and progesterone are essential regulators of uterine biology (5). The endometrium is particularly sensitive to steroid hormones, and long-term exposure to estrogens, unopposed by progesterone, may be a predisposing factor to EC (6). Progesterone is a well-studied steroid, in response to changes in the physiological conditions of the ovary and gonadotropin levels (7). Progesterone has been widely used in the patients who request to maintain their fertility and exhibit well-differentiated early-stage EC, or patients with recurrent or advanced-stage EC (8). However, the mechanism underlying progesterone therapy remains elusive.

Voltage-gated Ca\(^{2+}\) channels are protein complexes composed of a main, pore-forming α1 subunit and auxiliary α2δ and β subunits (9). α2δ subunits, encoded by one of the four genes CACNA2D1-CACNA2D4, consist of a larger extracellular glycosylated α2 peptide linked to a small membrane-anchored δ peptide (10). CACNA2D3, located at chromosome 3p21.1, has been reported to function in several types of cancer (11). Specific single nucleotide polymorphisms of CACNA2D3 (rs589281 and rs6797113) have been associated with poor clinical outcomes in esophageal cancer (12). Previous studies revealed that CACNA2D3 acts as a putative tumor suppressor in lung cancer (13), renal cell cancer (14) and esophageal squamous cell cancer (ESCC) (15). Recently, it has

Correspondence to: Dr Meijuan Cai or Dr Qian Wang, Department of Clinical Laboratory, Qilu Hospital of Shandong University, 107 Wenhua Xi Road, Jinan, Shandong 250012, P.R. China

E-mail: meijuancai85@163.com
E-mail: sd.wangqian@163.com

*Contributed equally

Key words: endometrial cancer, CACNA2D3, progesterone, cell apoptosis, mitogen-activated protein kinase pathway
been reported that CACNA2D3 enhances the chemosensitivity of ESCC to cisplatin by inducing Ca²⁺-mediated apoptosis and blocking the PI3K/AKT signaling pathways (16). CACNA2D3 CpG island is frequently methylated, and methylation-dependent transcriptional silencing of CACNA2D3 may contribute to a metastatic phenotype in breast cancer (17). In nasopharyngeal carcinoma, CACNA2D3 may mediate an increase in intracellular Ca²⁺ to induce apoptosis via the mitochondrial-pathway, thus reducing proliferation and invasion of cells (18). In addition, downregulation of CACNA2D3 is frequently detected in glioma (19). However, there are a few studies examining the association between CACNA2D3 and development of EC.

The aim of the present study was to examine the role of CACNA2D3 in EC progression and determine the association between CACNA2D3 and progesterone. Reverse transcription-quantitative (RT-qPCR) and western blotting were performed to examine the expression of CACNA2D3 in EC, and its expression was revealed to be downregulated in EC tissues and cells. In vivo, overexpression of CACNA2D3 significantly reduced tumor growth in Ishikawa and RL95-2 xenograft mice models. In addition, overexpression of CACNA2D3 reduced proliferation and migration, but increased apoptosis and Ca²⁺ influx in Ishikawa and RL95-2 cells. These results revealed that CACNA2D3 exhibited tumor suppressor functions in EC, and thus highlights a potential novel target for treatment of patients with EC. In an in vitro xenograft model, the injection of progesterone (P4) into nude mice attenuated Ishikawa-induced tumor growth and upregulated the expression of CACNA2D3. In vitro, treatment of cells with P4 also induced the expression of CACNA2D3. Knockdown of CACNA2D3 significantly reversed the P4-mediated reduction of proliferation and apoptosis. The addition of P4 increased the levels of intracellular Ca²⁺, phosphorylated (p)-p38 MAPK, phosphatase and tensin homolog (PTEN), and reduced the levels of p-PI3K and p-AKT. Silencing of CACNA2D3 significantly attenuated P4 function. Collectively, these data revealed that progesterone induced cell apoptosis by activation of the CACNA2D3/Ca²⁺/p38 MAPK pathway, but prevented cell proliferation and tumor growth through the inhibition of the PI3K/AKT pathway. These findings provide new evidence concerning the function of progesterone when used as a therapeutic option for patients with EC.

**Materials and methods**

**Patients and tissue samples.** A total of 15 EC tissues were isolated from patients who had undergone surgical resection or biopsies at Qilu Hospital of Shandong University (Shandong, China) between March 2017 and December 2018. The adjacent healthy endometrial tissues were used as the controls. None of the patients had undergone hormone therapy, intrauterine device usage, chemotherapy or radiotherapy for at least 6 months prior to surgery. All specimens were evaluated by at least two pathologists according to the World Health Organization (WHO) guidelines. The present study was approved by the Ethics Committees of Qilu Hospital of Shandong University [Approval no. (KYLL-2016(KS)-173)]. Permission from all the patients was obtained prior to the surgery. After operating, tissues were immediately frozen and stored in liquid nitrogen for follow-up experiments.

**Cell culture.** Human endometrium epithelial cells (EEC) were purchased from BeNa Culture Collection (Beijing, China) and cultured in Eagle's minimum essential medium with 10% FBS. Human endometrial cancer Ishikawa and RL95-2 cells were purchased from Shanghai GeneChem Co., Ltd. Cells were cultured in DMEM supplemented with 10% FBS at 37°C in a humidified atmosphere with 5% CO₂. For siRNA transfection, when confluence reached 80-90%, cells were transfected with negative control siRNA, (5'-AGCAUGCAU GAGUAACCCAGC-3') or CACNA2D3 siRNA (5'-CUCCGGU UUGCGAGCAUCUA-3') using Lipofectamine® 3000 (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol. After 48 h, transfected cells were prepared for subsequent experiments.

**Lentiviral vector construction and packaging.** The open reading frame of CACNA2D3 was inserted into a GV492 plasmid (Ubi-MCS-3FLAG-CBh-gcGFP-IRES-puromycin; Shanghai GeneChem Co., Ltd. 293T cells were purchased from BeNa Culture Collection (BNCC102182; Beijing, China) and were incubated in 25-cm² flasks in 4 ml DMEM containing 10% FBS. 293T cells were transfected with the GV492 vector or CACNA2D3-GV492, and the lentivirus package plasmid mixture. After 4 days, the supernatant was collected and filtered with a 0.45-µm membrane. Lentiviral particles ([LV-green fluorescent protein (GFP) and LV-CACNA2D3-GFP]) were harvested for cell infection.

Ishikawa or RL95-2 cells were infected with LV-GFP or LV-CACNA2D3-GFP lentiviral particles according to the manufacturer's protocol (Shanghai GeneChem Co., Ltd.). Ishikawa or RL95-2 cells were seeded into 6-well plates and infected with lentiviral particles under the optimum conditions of multiplicity of infection (MOI) of 20 or 30, respectively. After infection for 2-3 days, Puromycin was added to the cells to a final concentration of 2.5 µg/ml for clone selection. Medium was replaced every 3-4 days and puromycin added each time, until >95% of the cells were GFP-positive. Western blotting was used to examine the expression of target genes. Cells expressing GFP or CACNA2D3-GFP were used for subsequent experiments.

**Nude mouse xenograft cancer model.** A total of 12 female athymic nude mice (BALB/c; body weight, 18-20 g; age 6-7 weeks) were purchased from Sino-British Experiment Animals and divided into two groups: the vector and CACNA2D3 groups. Mice were housed under specific-pathogen-free conditions in a laminar air-flow cabinet maintained at 25°C with 50±10% humidity and a 12-h dark/light cycle. Mice had free access to water and food throughout the study. All animal studies were performed in accordance with the protocols approved by the Ethics Committee of Qilu Hospital of Shandong University [Approval no. (KYLL-2016(KS)-173)]. Mice in the CACNA2D3 group were subcutaneously injected with 1x10⁶ LV-CACNA2D3-GFP-infected cells in 100 µl PBS into the right flank. Mice in the vector group were administered with the same volume of cells infected with LV-GFP. The tumor volume was calculated every 7 days according to the following formula: Volume (mm³) = width² x length/2. After 30 days, tumor tissues were isolated and captured with a digital camera (Nikon Corp.).
**RT-qPCR.** Total RNA was extracted from cells using TRIzol® reagent (Beyotime Institute of Biotechnology). A total of 1 µg RNA was transcribed into cDNA using M-MLV Reverse Transcription Kit (BioTeke Corporation). RT-qPCR was performed using a Biosystem StepOne Plus PCR system (Applied Biosystems; Thermo Fisher Scientific, Inc.) with SYBR Green real-time PCR master mix (Takara Bio, Inc.) using the following thermocycling conditions: 95°C for 5 min; followed by 40 cycles at 95°C for 20 sec and 60°C for 20 sec. The relative expression of CACNA2D3 was normalized to GAPDH using the 2^(-ΔΔCq) method (20). The sequences of the primers were: CACNA2D3 forward, 5'-tccgagggaatgtaacca-3'; and reverse, 5'-gagacagatggcggtgct-3'; and GAPDH forward, 5'-gccttacacctcatatc-3' and reverse, 5'-gttagcaggtgatgttc-3'. The experiments were performed in triplicate with independent experimental samples.

**Colony formation assay.** Ishikawa and RL95-2 cells expressing GFP or CACNA2D3-GFP were seeded into 6-well plates at a density of 200 cells/well in a humidified incubator with 5% CO₂. After 10 days, cells were fixed with methanol for 10 min at room temperature and subsequently stained with 0.5% crystal violet (Beyotime Institute of Biotechnology) for 30 min at room temperature. Visible clones were imaged using a digital camera (Nikon Corporation). Experiments were independently repeated three times.

**MTT assay and EdU staining.** For the MTT assay, Ishikawa and RL95-2 cells expressing GFP or CACNA2D3-GFP were seeded into 96-well plates at a density of 1x10³ cells/well. After 48, 72 or 96 h, 10 µl MTT solution (5 mg/ml) and 150 µl DMEM was added to each well for 10 min at 37°C in the dark, after which, the absorbance was measured at 562 nm using an automatic microplate reader (Thermo Fisher Scientific, Inc.). The assay was repeated at least three times.

For EdU staining, Ishikawa and RL95-2 cells expressing GFP or CACNA2D3-GFP in the logarithmic growth phase were seeded into 24-well plates and incubated with 50 µM of EdU for 4 h at 37°C and fixed with 4% paraformaldehyde solution for 20 min at room temperature. After washing with PBS, the cells were permeabilized with 0.2% Triton X-100 in PBS at 37°C for 30 min and washed again with PBS. Subsequently, cells were treated with 100 µl 1X Apollo reaction cocktail for 30 min, and stained with DAPI (1 µg/ml) for 30 min and visualized under a fluorescence microscope (Nikon Corp.).

**Transwell invasion assay.** For the Transwell invasion assays, the upper side of an 8-µm pore, 6.5-mm polycarbonate Transwell filter (Corning, Inc.) chamber was uniformly coated with Matrigel basement membrane matrix (BD Biosciences) for 2 h at 37°C prior to the cells being added. A total of 2x10⁵ cells in 200 µl DMEM without FBS were seeded into the upper well, and 700 µl medium supplemented with 10% FBS was added to the lower chamber. After incubation at 37°C for 48 h, the cells which had adhered to the lower well were fixed with 4% paraformaldehyde, stained with 0.5% crystal violet (Beyotime Institute of Biotechnology) for 10 min, and counted using an Olympus IX51 inverted microscope in five randomly selected fields of view and images were captured at an x200 magnification.

**Intracellular Ca²⁺ measurement.** Cells were washed with PBS three times and stained with 1 µM Fluo-3 AM (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol. After 48 h, the cells in the P4 or P4+CACi groups were treated with 1 µM P4. After 2 days, the cells were collected and stained with 50 µl Annexin V-FITC and 10 µl PI. After incubation at room temperature in the dark for 15 min, 400 µl of 1X binding buffer was added, and flow cytometry was performed using excitation and emission wavelengths of 488 and 546 nm on a FACSort flow cytometer (BD Biosciences). Each sample was examined to determine the percentage of cancer cells exhibiting Annexin V+/PI (+/+/-) staining in (early apoptosis) or Annexin V/PI (+/+/-) staining (late apoptosis or cell death stage).

**Immunohistochemistry (IHC).** Tumor tissues were extracted from mice and fixed with 4% fresh cold paraformaldehyde at 4°C overnight. The following morning, tissues were embedded in paraffin wax and cut into 5 to 7-µm thick sections. Sections were treated with 3% hydrogen peroxide in methanol for 20 min at room temperature to block the activity of endogenous peroxidases. After blocking with 5% bovine serum albumin (Sangon Biotech Co., Ltd.) at room temperature for 1 h, the sections were incubated with rabbit polyclonal antibody against CACNA2D3 (ID product code ab102939; 1:300; Abcam) at 4°C overnight. After washing with PBS, the sections were probed with goat anti-rabbit immunoglobulin G heavy and light chain horseradish peroxidase (ID product code ab6721; 1:1,000; Abcam) at 37°C for 1 h. Signals were developed with diaminobenzidine-H₂O₂ solution and captured with an inverted microscope (Nikon Corporation) from five non-overlapping high-powered fields. Positive cells were marked in brown or dark yellow.

**Apoptosis analysis.** Apoptosis was evaluated using an Annexin V-fluorescein isothiocyanate (FITC)/propidium iodide (PI) kit (Beyotime Institute of Biotechnology). Cells in the logarithmic growth phase were seeded into 96-well plates and randomly divided into three groups: Control, P4 and P4+CACi groups. Cells in P4 or P4+CACi groups were transfected with NC siRNA or CACNA2D3 siRNA using Lipofectamine® 3000 (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol. After 48 h, the cells in the P4 or P4+CACi groups were treated with 1 µM P4. After 2 days, the cells were collected and stained with 50 µl Annexin V-FITC and 10 µl PI. After incubation at room temperature in the dark for 15 min, 400 µl of 1X binding buffer was added, and flow cytometry was performed using excitation and emission wavelengths of 488 and 546 nm on a FACSort flow cytometer (BD Biosciences). Each sample was examined to determine the percentage of cancer cells exhibiting Annexin V+/PI (+/+/-) staining in (early apoptosis) or Annexin V/PI (+/+/-) staining (late apoptosis or cell death stage).

**Western blotting.** Proteins were isolated from tissues or cells with RIPA buffer (Sigma-Aldrich; Merck KGaA). Protein concentrations were determined using a BCA kit (Pierce Biotechnology, Inc.; Thermo Fisher Scientific, Inc.) according to the manufacturer's instructions. Equal amounts of protein (30 µg/lane) were subjected to 10% sodium dodecyl sulfate-polyacrylamide electrophoresis and transferred onto polyvinylidene difluoride membranes (EMD Millipore). After being blocked with 5% non-fat milk at room temperature for 1 h, the membranes were incubated with rabbit antibodies against CACNA2D3 (ID product code ab102939; 1:500), GAPDH (ID product code ab37168; 1:500), extracellular...
signal-regulated protein kinase 1/2 (ERK1/2; ID product code ab17942; 1:1,000), p-ERK1/2 (ID product code ab223500; 1:400), c-Jun N-terminal kinase (JNK; ID product code ab112501; 1:1,000), p-JNK (ID product code ab13499; 1:1,000), p38 mitogen-activated protein kinase (p38 MAPK; ID product code ab27986; 1:500), p-p38 MAPK (ID product code ab60999; 1:500), protein kinase B (AKT1; ID product code ab227100; 1:1,000), p-AKT1 (ID product code ab8933; 1:500), phosphatidylinositol 3-kinase (PI3K; ab70912; 1:100), p-PI3K (ID product code ab32089; 1:1,000) and PTEN (ID product code ab31392; 1:1,000) (all from Abcam) overnight at 4°C. The following morning, the membranes were washed with TBST and incubated with goat anti-rabbit IgG H&L (HRP) (ID product code ab6721; 1:5,000; Abcam) at 37°C for 1 h. The membranes were visualized using an enhanced chemiluminescence system (ImageQuant LAS4000) by the normalization to GAPDH. The band density was determined by relative densitometry using ImageJ Software version 1.50 (National Institutes of Health). The experiments were conducted in triplicate with independent experimental samples.

Statistical analysis. Data are presented as the mean ± standard deviation of three repeats. Statistical analysis was performed using IBM SPSS Statistics 25.0 (IBM Corp.) with a Student’s t-test. P<0.05 was considered to indicate a statistically significant difference.

Results

CACNA2D3 expression is downregulated in EC tissues and cells. The mRNA and protein expression levels of CACNA2D3 were measured in EC tissues compared with the adjacent noncancer tissues using RT-qPCR and western blotting. Compared with the adjacent noncancer tissues, the mRNA expression levels of CACNA2D3 in EC tissues was significantly decreased (Fig. 1A; P<0.01). A similar trend was observed in the protein expression levels in four pairs of EC cases (Fig. 1B). As revealed in Fig. 1C and D, the mRNA and protein expression levels in the human EC cell lines, Ishikawa and RL95-2, were significantly decreased compared with the EEC cells (P<0.01). These data revealed that CACNA2D3 expression was downregulated in EC tissues and cells.

Overexpression of CACNA2D3 inhibits tumor growth in vivo. To examine the effect of CACNA2D3 on tumor growth, LV-GFP (vector group) and LV-CACNA2D3-GFP-infected (CACNA2D3 group) cells were subcutaneously injected into the flanks of 5-week-old male nude mice. As revealed in Fig. 2A-a, green fluorescent signals were observed in the vector and CACNA2D3 groups, indicating that Ishikawa cells were successfully infected with virus particles. The mRNA and protein expression levels of CACNA2D3 were significantly upregulated in the CACNA2D3 group displayed in Fig. 2A-b and c (P<0.01), indicating that CACNA2D3 was successfully expressed in the CACNA2D3 group. In Fig. 2A-d and e, the tumor volume was calculated every 7 days and tumor tissues were extracted after 30 days. The results revealed that the tumor size in the CACNA2D3 group was significantly smaller compared with the vector group (P<0.01). Compared with the vector group, the protein levels of CACNA2D3 in mice injected with LV-CACNA2D3-GFP-infected cells were significantly increased, indicating that CACNA2D3 was successfully expressed in vivo as shown in Fig. 2A-f. Similar results were observed following injection with the RL95-2 cells (Fig. 2B-a-f). Collectively, these data indicated that overexpression of CACNA2D3 inhibits tumor growth in vivo.

CACNA2D3 suppresses cell proliferation and migration, and induces cell apoptosis and Ca2+ influx. A colony formation assay, MTT assay, EdU staining, Transwell invasion assay and flow cytometry were used to examine the effect of CACNA2D3 on cell proliferation, migration and apoptosis. Ishikawa and RL95-2 cells were infected with LV-GFP or LV-CACNA2D3-GFP. In Fig. 3A, western blotting results revealed that CACNA2D3 was successfully expressed in transfected Ishikawa and RL95-2 cells. Overexpression of CACNA2D3 significantly reduced the number of clones formed compared with the vector group (Fig. 3B and C; P<0.01), indicating that CACNA2D3 prevents colony formation in Ishikawa and RL95-2 cells. Optical density (OD) values at 560 nm in the CACNA2D3 group was significantly lower compared with the vector group (Fig. 3D and E; P<0.01). The number of EdU-positive cells in the CACNA2D3 group was also significantly decreased (Fig. 3F). The aforementioned results demonstrated that overexpression of CACNA2D3 inhibited cell proliferation in Ishikawa and RL95-2 cells. In order to examine the effects of CACNA2D3 on cell invasion, Transwell invasion assays were performed (Fig. 3G and H). The number of cells that adhered to the lower well in the CACNA2D3 group was significantly lower compared with the vector group (P<0.01), indicating that CACNA2D3 prevented invasion. The proportion of cells characterized as Annexin V/PI (+/-) and Annexin V/PI (+/+ in the CACNA2D3 group was significantly increased compared with the Vector group (Fig. 4A and B), indicating that overexpression of CACNA2D3 induced cell apoptosis. Overexpression of CACNA2D3 resulted in an increase in intracellular Ca2+ levels as detected by Fluo-3 AM staining. Collectively, these results indicated that CACNA2D3 inhibited cell proliferation and migration, and induced apoptosis and Ca2+ influx.

In order to determine the mechanism by which CACNA2D3 affected cell proliferation, cell migration and cell apoptosis, the activation of ERK, JNK, MAPK and AKT pathways following overexpression of CACNA2D3 was examined (Fig. 4D-K). Compared with the Vector group, overexpression of CACNA2D3 significantly increased the protein expression levels of CACNA2D3 (Fig. 4E), p-p38 MAPK (Fig. 4H) and PTEN (Fig. 4I), and reduced the levels of p-PI3K (Fig. 4J) and p-AKT (Fig. 4K). These data revealed that CACNA2D3 exerted tumor suppressor activity in EC by regulating MAPK and the PI3K/AKT pathways.

P4 suppresses tumor growth and cell proliferation via CACNA2D3 and increasing intracellular Ca2+ levels. To evaluate the anticancer effects of P4 in an in vivo xenograft model, nude mice were injected with Ishikawa cells and treated with P4. Compared with the mice injected with Ishikawa cells alone, the addition of P4 significantly reduced tumor size (Fig. 5A and B). IHC and western blot analysis revealed that CACNA2D3 was overexpressed following treatment with P4 (Fig. 5C and D), suggesting that the P4-mediated reduction in tumor volume...
may be associated with upregulation of CACNA2D3. In order to verify this hypothesis, the effect of P4 on the expression of CACNA2D3 in Ishikawa cells was determined. As revealed in Fig. 5E, P4 application significantly upregulated the protein expression levels of CACNA2D3 (P<0.01). In addition, compared with the control group, P4 application reduced the OD value at 560 nm (Fig. 5F). However, the knockdown of CACNA2D3 mitigated P4-mediated reduction in cell proliferation. As revealed in Fig. 5G and H, the apoptotic rate in the P4 group was significantly higher compared with the control group (P<0.01), however, silencing of CACNA2D3 decreased the increase in apoptotic rate induced by P4 (P<0.01). The intracellular Ca\(^{2+}\) levels in the P4 group were significantly increased compared with the control group (Fig. 5I; P<0.01), whereas knockdown of CACNA2D3 resulted in a decrease in intracellular Ca\(^{2+}\) levels. These data revealed that P4 prevents tumor growth via CACNA2D3 and an increase in intracellular Ca\(^{2+}\) levels.

P4 activates the p38 MAPK pathway and suppresses the PI3K/AKT pathway via CACNA2D3. To further investigate the mechanism by which P4 induced cell apoptosis and blocked cell proliferation in Ishikawa cells, the activation of the ERK, JNK, MAPK and AKT pathways was investigated following the application of P4. Compared with the control group, the addition of P4 significantly increased the protein expression levels of CACNA2D3 (Fig. 6B), p-p38 MAPK (Fig. 6E) and PTEN (Fig. 6F), but reduced the levels of p-PI3K (Fig. 6G) and p-AKT (Fig. 6H). Silencing of CACNA2D3 significantly reversed the increase in expression of CACNA2D3, p-p38 MAPK and PTEN induced by P4, and resulted in an increase in the levels of p-PI3K and p-AKT. In addition, neither P4 nor silencing of CACNA2D3 had any notable effect on the expression of p-ERK1/2 (Fig. 6C) and p-JNK (Fig. 6D). Collectively, P4 activated the p38 MAPK and suppressed the PI3K/AKT pathways through the activation of CACNA2D3 (Fig. 6I).

---

Figure 1. CACNA2D3 expression is downregulated in EC tissues and cells. (A and B) mRNA and protein expression levels of CACNA2D3 in EC and non-tumor tissues. (C and D) mRNA and protein expression levels of CACNA2D3 in EEC, Ishikawa and RL95-2 cells. EC, endometrial cancer; EEC, endometrial epithelial cell. **P<0.01.
Discussion

CACNA2D3 is a member of the Ca²⁺ channel regulatory α2δ subunit family and is localized at chromosome 3p21.1 (14). It has been reported that CACNA2D3 functions as a tumor suppressor in a number of different types of cancer, such as lung cancer (13), breast cancer (17) and renal cell cancer (14). However, the function of CACNA2D3 in EC remains unknown. In the
present study, RT-qPCR and western blot analysis revealed that the mRNA and protein expression levels of CACNA2D3 were reduced in EC tissues and cells, indicating that CACNA2D3 may also function as a putative tumor suppressor in EC. In an in vivo xenograft model, the overexpression of CACNA2D3 via lentiviral infection significantly suppressed tumor growth. Overexpression

Figure 3. CACNA2D3 decreases cell proliferation and migration. (A) CACNA2D3 expression was increased in Ishikawa and RL95-2 cells infected with CACNA2D3-GFP. "P<0.01. (B and C) Overexpression of CACNA2D3 decreased the number of clones formed by Ishikawa and RL95-2 cells. Overexpression of CACNA2D3 decreased cell proliferation as detected by (D and E) MTT assay and (F) EdU staining. (G and H) Overexpression of CACNA2D3 decreased invasion. "P<0.01. GFP, green fluorescent protein.
KONG et al.: PROGESTERONE ACTIVATES THE CACNA2D3/Ca^{2+}/p38 MAPK PATHWAY

Figure 4. CACNA2D3 increases apoptosis, intracellular Ca^{2+} levels and activates the p38 MAPK pathway. (A and B) CACNA2D3 overexpression increased apoptosis as detected by flow cytometry. (C) Overexpression of CACNA2D3 resulted in an increase in intracellular Ca^{2+} levels. (D-K) CACNA2D3 regulated the protein expression levels of ERK, JNK, MAPK and AKT. **P<0.01.
Figure 5. P4 suppresses tumor growth and cell proliferation by upregulating CACNA2D3 expression and increasing intracellular Ca²⁺. (A and B) Addition of P4 decreased the tumor volume in mice injected with Ishikawa cells. (C and D) CACNA2D3 expression was increased when treated with P4. (E) Treatment with P4 increased the protein expression levels of CACNA2D3 in Ishikawa cells. (F) P4 reduced proliferation of cells. (G) Flow cytometry was performed to examine cell apoptosis. (H) Apoptotic percentage of cells treated with or without P4. (I) P4 increased the intracellular Ca²⁺ levels. Cells were incubated with Fluo-3 AM. Flow cytometric analysis was performed to assess the intracellular Ca²⁺ concentration. **P<0.01. P4, progesterone.
KONG et al.: PROGESTERONE ACTIVATES THE CACNA2D3/Ca2+/p38 MAPK PATHWAY

of CACNA2D3 in vitro significantly inhibited cell proliferation and migration, and induced cell apoptosis and Ca2+ influx. These data indicated that CACNA2D3 acts as a tumor suppressor in EC. The data in the present study demonstrated the function of CACNA2D3 in EC and improved our understanding of the role of CACNA2D3 in different types of cancer. These findings highlight a novel potential target for treating patients with EC.

EC is a hormone-regulated cancer, estrogen drives its growth, and progesterone suppresses its proliferation and leads to differentiation (21). Insufficient progesterone to oppose estrogen-driven proliferation is one of the primary causes of the development and formation of EC (22). Therefore, progesterone has been widely used for EC therapy, especially for younger patients with EC with a
In vivo by which P4 reduced cell proliferation and promoted apoptosis and induced cell apoptosis as determined using MTT and flow cytometric assays in Ishikawa cells. These results provide new evidence that progesterone prevents the development of EC. However, the mechanism by which P4 reduced cell proliferation and promoted apoptosis remains unknown. In vivo and in vitro, the addition of P4 upregulated the expression of CACNA2D3 and silencing of CACNA2D3 impaired the function of P4 on cell apoptosis and proliferation. Previous research has reported that CACNA2D3 inhibits cell proliferation and promotes cell apoptosis in glioma (19), nasopharyngeal carcinoma (18) and esophageal squamous cell carcinoma (16). Therefore, in the present study it was hypothesized that P4 regulation of cell apoptosis and cell proliferation involved CACNA2D3.

The MAPK pathways have been demonstrated to serve an important role in the regulation of many cell biological behaviors, such as cell proliferation and cell apoptosis (25). An increase in cytoplasmic Ca2+ levels activates the MAPK cascade (26, 27). Three distinct groups of MAPKs, including ERK1/2, JNK, and p38 MAPK, are important for cancer cell apoptosis (28). To examine the signaling pathways behind the effects of CACNA2D3 and P4 on Ishikawa cell apoptosis, the activity of ERK, JNK and p38 MAPK pathways was measured following CACNA2D3 overexpression or P4 treatment. The results indicated that the overexpression of CACNA2D3 induced an increase in intracellular Ca2+ and increased the levels of p-p38 MAPK. These data indicated that the p38 MAPK pathway is activated by overexpression of CACNA2D3 and P4 induction. However, silencing of CACNA2D3 significantly resulted in reduced p-p38 MAPK levels induced by P4. These findings revealed that P4 induced the phosphorylation of p38 MAPK, via CACNA2D3/Ca2+/p38 MAPK and highlights a novel mechanism by which P4 induced cell apoptosis in EC.

The activation of the PI3K/AKT pathway serves a crucial role in control of cell growth and proliferation in endometrial cancer (29). PTEN is one of the most frequently observed tumor suppressor genes in different types of cancer (30). The PI3K/AKT pathway has been revealed to be negatively regulated by PTEN (31). A previous study reported that increased PTEN expression levels facilitated the reduction in PI3K and AKT activity (32). In the present study, CACNA2D3 overexpression increased the expression of PI3K, but reduced the levels of p-PI3K and p-AKT, indicating that CACNA2D3 regulates the PI3K/AKT pathway. Similarly, it was demonstrated that P4 enhanced the expression of PTEN, in agreement with a previous study (33). In addition, P4 significantly reduced the levels of p-PI3K and p-AKT, and this reduction was mitigated by silencing of CACNA2D3. Therefore, P4 disrupted the activation of PI3K/AKT via CACNA2D3.

In summary, CACNA2D3 exerted a tumor suppressor function in EC, thus highlighting a potential novel target for the treatment of EC. In addition, it was demonstrated that P4 promoted cell apoptosis via the activation of the CACNA2D3/Ca2+/p38 MAPK pathway, and P4 blocked cell proliferation via disruption of the PI3K/AKT pathway through CACNA2D3. These findings revealed that progesterone may function in EC therapy by activating CACNA2D3. However, there are some limitations in the present study. First, the number of EC patients in the study was relatively small and may thus be insufficient. A larger set of patients from multiple centers are required to confirm these results. Second, although P4 upregulated the expression of CACNA2D3 in vivo and in vitro, the underlying mechanism by which P4 upregulated CACNA2D3 expression requires further study. A previous study revealed that P4 function may be mediated through a traditional genomic pathway and non-genomic signaling (34). Whether P4 activates the expression of CACNA2D3 through the genomic or non-genomic pathway remains unknown.

Acknowledgements

Not applicable.

Funding

The present research was supported by the National Natural Science Fund (no. 81602271), the Qingdao Applied Basic Research Source Innovation Plan (no. 17-1-1-43-jch) and the Qingdao Outstanding Health Professional Development Fund.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

XK and ML performed the experiments. KS and YY incubated the cells and constructed the mouse models. QW analyzed the data and corrected the manuscript. MC designed the experiments and wrote the original manuscript. All authors read and approved the final manuscript and agree to be accountable for all aspects of the research in ensuring that accuracy or integrity of any parts of the work are appropriately investigated and resolved.

Ethics approval and consent to participate

All patients signed an informed consent form, and the present study was approved by the Ethics Committees of Qilu Hospital of Shandong University [Approval no. (KYLL-2016(KS)-173)]. All animal studies were performed in accordance with the protocols approved by the Ethics Committee of Qilu Hospital of Shandong University [Approval no. (KYLL-2016(KS)-173)].

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing of interests.
References

1. Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E and Vergote I: Endometrial cancer. Lancet 366: 491-505, 2005.

2. Su Y, Wang J, Ma Z, Gong W and Yu L: miR-142 suppresses endometrial cancer proliferation in vitro and in vivo by targeting cyclin D1. DNA Cell Biol 38: 144-150, 2019.

3. Teng F, Tian WY, Wang YM, Zhang YF, Guo F, Zhao J, Gao C and Xue FX: Cancer-associated fibroblasts promote the progression of endometrial cancer via the SDF-1/CXCR4 axis. J Hematol Oncol 9: 8, 2016.

4. Liu B, Che Q, Qiu H, Bao W, Chen X, Lu W, Li B and Wan X: Elevated MiR-222-3p promotes proliferation and invasion of endometrial carcinoma via targeting ERα. PLoS One 9: e87563, 2014.

5. Jiang Y, Chen L, Taylor RN, Li C and Zhou H: Physiological and pathological implications of retinoid action in the endometrium. J Endocrinol 236: R169-R186, 2018.

6. Chi S, Liu Y, Zhou X, Feng D, Xiao X, Li W, Zhao Y and Wang H: Knockdown of long non-coding HOTAIR enhances the sensitivity to progesterone in endometrial cancer by epigenetic regulation of progesterone receptor isoform B. Cancer Chemother Pharmacol 83: 277-287, 2019.

7. Adams NR and DeMayo FJ: The role of steroid hormone receptors in the establishment of pregnancy in rodents. Adv Anat Embryol Cell Biol 216: 27-49, 2015.

8. Park JY, Kim DY, Kim TJ, Kim JW, Kim JH, Kim YM, Kim YT, Bae DS and Nam JH: Hormonal therapy for women with stage IA endometrial cancer of all grades. Obstet Gynecol 122: 7-14, 2013.

9. Pirone A, Kurt S, Zuccotti A, Ruttiger L, Pilz P, Brown DH, Guzeloglu-Kayisli O, Kayisli UA, Al-Rejjal R, Zheng W, Luleci G and Arici A: Regulation of PTEN (phosphatase and tensin homolog deleted on chromosome 10) expression in response to progesterone reduces endometriotic lesion data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408, 2001.

10. Qin YR, Fu L, Sham PC, Kwong DL, Zhu CL, Chu KK, Li Y and Ng PK: High-throughput loss-of-heterozyosity study of chromosome 3p in lung cancer using single-nucleus polymerase markers. Cancer Res 66: 4133-4138, 2006.

11. Hanke S, Bugert P, Chudek J and Kovacs G: Cloning a calcium channel alpha(2)delta-3 subunit. Mol Pharmacol 62: 220-228, 2007.

12. Teng F, Tian WY, Wang YM, Zhang YF, Guo F, Zhao J, Gao C and Xue FX: Cancer-associated fibroblasts promote the progression of endometrial cancer via the SDF-1/CXCR4 axis. J Hematol Oncol 9: 8, 2016.

13. Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Medeiros Alencar VH, Badran A, Bonfill X, et al: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer. ATLAS, a randomised trial. Lancet 381: 805-816, 2013.

14. Pfeiffer RM, Park Y, Kreimer AR, Lacey JV Jr, Gee D, Greenlee RT, Buys SS, Hollebeck A, Rosner B, Gail MH and Hartge P: Risk prediction for breast, endometrial, and ovarian cancer in white women aged 50 y or older: Derivation and validation from population-based cohort studies. PLoS Med 10: e1001492, 2013.

15. Cheng M, Michalski S and Kommagani R: Role for growth regulation by estrogen in breast cancer I (GREB1) in hormone-dependent cancers. J Mol Sci 19: E2543, 2018.

16. Yuan DZ, Lei Y, Zhao D, Boon M, Zhang Q, Nie L, Liu M, Long Y, Zhang JH and Yue LM: Progestosterone-induced miR-145/miR-143 inhibits the proliferation of endometrial epithelial cells. Reprod Sci 26: 233-243, 2019.

17. Wei Y, Jin Z, Zhang H, Piao S, Lu J and Bai L: The transient receptor potential channel, vanilloid 5, induces chondrocyte apoptosis via Ca(2+)-CaMKII-Dependent MAPK and Akt/mTOR pathways in a rat osteoarthritis model. Cell Physiol Biochem 51: 2309-2323, 2018.

18. Song Z, Wang Y, Zhang F, Yao F and Sun C: Calcium Signaling Pathways: Key Pathways in the Regulation of Obesity. Int J Mol Sci 20: pii: E2768, 2019.

19. Malloy KM, Wang J, Clark LH, Fang Z, Sun W, Yin Y, Kong W, Zhou C and Bae-Jump VL: Novasoy and genistein inhibit endometrial cancer cell proliferation through disruption of the AKT/mTOR and MAPK signaling pathways. Am J Transl Res 10: 784-795, 2018.

20. Choi J, Jo M, Lee E, Hwang S and Choi D: Aberrant PTEN expression in response to progesterone reduces endometriotic stromal cell apoptosis. Reproduction 153: 11-21, 2017.

21. Zhao Z and Yu H: miR-205 inhibits cell growth by targeting AKT-mTOR signaling in progesterone-resistant endometrial cancer Ishikawa cells. Oncotarget 8: 28042-28051, 2017.

22. Hao X, Qiu T, Mao J, Zhang J, Fan S, Lu Y, Sun Z, Zhang Q, Song B and Li L: PTEN/Pi3K/mTOR pathway contributes to breast cancer progression by regulating PTEN via PI3K/AKT pathway. J Exp Clin Cancer Res 38: 256, 2019.

23. Umezawa H, Tsuchiya H, Isobe Y and Komatsu N: Progesterone-activated Ca(2+)-CaMKII Activity Enhances Cell Proliferation by Induction of a Progesterone Receptor-Cyclin D1-MAPK Pathway. J Mol Endocrinol 28: 656-668, 2017.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.